Pfizer Inc. agreed to pay $43bn in cash for antibody-drug conjugate (ADC) developer Seagen Inc. earlier this month. The US pharma giant said Seagen’s four approved products – three ADCs and a small molecule cancer drug – plus candidates in its pipeline should generate $10bn in annual revenue by 2030. This puts Pfizer less than $5bn away from achieving its goal of adding $25bn in new revenue by 2030 through business development activities.
That level of investment is needed to offset losses of exclusivity (LOEs) later in this decade for multiple blockbuster products,...